Brain Injury Linked to Adult Growth Hormone Deficiency: Diagnosis and Treatment Explored

Adult Growth Hormone Deficiency (aGHD) is a complex endocrine disorder characterized by insufficient production of growth hormone from the pituitary gland. This deficiency can manifest with a range of debilitating symptoms, including reduced bone mineral density, decreased muscle mass, increased adiposity, and impaired quality of life. A significant and often overlooked cause of secondary aGHD is brain injury, encompassing conditions like traumatic brain injury (TBI), subarachnoid hemorrhage, or radiation-induced damage to the hypothalamus-pituitary axis. Accurate and timely diagnosis, alongside effective treatment strategies for aGHD following brain injury, is paramount for mitigating long-term complications and improving patient well-being.

The review highlights that diagnosing aGHD in brain-injured patients can be particularly challenging due to overlapping symptoms with post-concussion syndrome and other neurological sequelae. However, it underscores the importance of systematic screening. Recombinant human growth hormone (rhGH) replacement therapy is presented as a highly effective intervention for improving the clinical manifestations of aGHD. > Numerous studies consistently demonstrate that rhGH treatment can lead to significant improvements in body composition, with typical reductions in fat mass by 5-10% and increases in lean body mass by 2-4% over 6-12 months of therapy, alongside enhanced bone mineral density. Patients often report a substantial improvement in their quality of life, including reduced fatigue and enhanced cognitive function, with up to 70% of treated individuals experiencing symptomatic relief. Furthermore, long-term therapy can lead to increases in bone mineral density by 1-3% annually, reducing fracture risk.